Shots:

• The P-III (KEYNOTE-006) trial assessed Keytruda vs ipilimumab to treat advanced melanoma; participants could transition to the KEYNOTE-587 extension study for long-term follow-up. Results include 10yrs. follow-up data for 211 patients
• Results at a median follow-up of 123.7mos. (time of study entry in KEYNOTE-006 to data cut-off for KEYNOTE-587) showed improved OS & PFS, with an mOS of 32.7mos. vs 15.9mos. and a 10yr. OS rate of 34% vs 23.6%, modified mPFS was 9.4mos. vs 3.8mos. Keytruda reduced death risk by 29%
• The final analysis of KEYNOTE-006 at a median follow-up of 32mos. showed 55.1% (Q2W) & 55.3% (Q3W) vs 43.0% of patients were alive at 2yrs. Data was published in the Annals of Oncology

Ref: Merck | Image: Merck

Related News:- GI Innovation Join Forces with Merck to Evaluate GI-102 Plus Keytruda for Treating Various Cancers

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com